Bayer to build $2.2 billion drug manufacturing plant in Ohio
The site will produce oncology, cardiovascular and renal treatments, with Bayer's drug-substance module due online in 2031
Published
Bayer will invest $2.2 billion in a new manufacturing site in New Albany, Ohio, the company said. The facility will make drug substances and finished products for oncology, cardiovascular and renal care.
The drug-substance module is expected to start operating in 2031, with the drug-product module following in 2034, according to a Bayer press release carried by Business Wire. The campus will be modular and combine substance and product manufacturing with automation and digital tools, JobsOhio said.
JobsOhio said the project will create around 600 permanent jobs and roughly 1,500 construction jobs. Ohio Governor Mike DeWine said Bayer could have built the plant anywhere in the country but chose Ohio, according to the JobsOhio release. The investment adds to more than $7 billion Bayer has put into US pharmaceutical research and manufacturing over the past five years, JobsOhio said, and dwarfs the $44 million Bayer committed to a Pennsylvania facility in April 2025.
A plant of this size takes years to build, so the commitment points to a multi-year bet on US demand rather than an immediate boost to earnings. It also signals Bayer is moving manufacturing onshore ahead of potential new drug launches, including Lynkuet if it clears US regulatory review, and that the company is leaning on its drug pipeline, not just the legal overhang from litigation, to drive its turnaround. The spending adds to Bayer's near-term capital outlay without changing the approval or sales outlook for any specific drug.